Regenomics represents the merger of two fields of scientific endeavor: Regenerative medicine and genomics.
New technologies to reprogram aged somatic cells back to pluripotency and to restore telomere length are currently used in research in regenerative medicine, though FDA-approved cellular therapies using reprogrammed cells are currently not available in the United States. The culture and banking of somatic cells also allows the parallel sequencing of their nuclear DNA to provide individuals with potentially valuable information for guiding them in lifestyle choices, but also one day, potentially in preventative strategies where cell types are made in advance for high risk categories of disease, i.e. preparing cardiac progenitor cells for individuals at high risk for heart disease.
|
